In vivo rat glandular stomach and colon micronucleus tests: Kinetics of micronucleated cells, apoptosis, and cell proliferation in the target tissues after a single oral administration of stomach- or colon-carcinogens

Author(s):  
Wakako Ohyama ◽  
Emiko Okada ◽  
Yohei Fujiishi ◽  
Kazunori Narumi ◽  
Nobuyoshi Yasutake
1994 ◽  
Vol 56 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Shinji Yamamura ◽  
Kenichiro Okadome ◽  
Toshihiro Onohara ◽  
Kimihiro Komori ◽  
Keizo Sugimachi

2020 ◽  
Vol 8 (1) ◽  
pp. 60
Author(s):  
Ashraf Elkomy ◽  
Mohamed Aboubakr

The present study was designed to assess the comparative bio-equivalence of Lincopharm 800® and Lincoyosr® in healthy broiler chicken after oral administration of both products in a dose of 20 mg lincomycin base/kg b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Lincopharm 800®, while the 2nd group was designed to study the pharmacokinetics of Lincoyosr®. Each broiler chicken in both groups was orally administered with 20 mg lincomycin base/kg b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after a single oral administration. The disposition kinetics of Lincopharm 800® and Lincoyosr® following oral administration of 20 mg lincomycin base /kg b.wt, revealed that the maximum blood concentration of lincomycin [Cmax] were 4.81 and 4.62 μg/ml and attained at [tmax] of 1.36 and 1.35 hours, respectively. In conclusion: Lincoyosr® is bioequivalent to Lincopharm 800® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.96, 0.92 and 0.91 respectively. These are within the bioequivalence acceptance range. Lincoyosr® and Lincopharm 800® are therefore bioequivalent and interchangeable.   


2020 ◽  
Vol 8 (1) ◽  
pp. 54
Author(s):  
Ashraf El-Komy ◽  
Mohamed Aboubakr

The present study was designed to assess the comparative bio-equivalence of Doxycycline Kela 75%® and Mebcodox 75%® in healthy broiler chickens after oral administration of both products in a dose of 20 mg doxycycline base/kg.b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Doxycycline Kela 75%®, while the 2nd group was designed to study the pharmacokinetics of Mebcodox 75%®. Each broiler chickens in both groups were orally administered with 20 mg doxycycline base/kg.b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after a single oral administration The disposition kinetics of Doxycycline Kela 75%® and Mebcodox 75%® following oral administration of 20 mg doxycycline base/kg.b.wt. revealed that the maximum blood concentration [Cmax] were 3.35 and 3.28 μg/ml and attained at [tmax] of 0.97 and 0.99 hours, respectively.In conclusion: Mebcodox 75%® is bioequivalent to Doxycycline Kela 75%® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.97, 0.95 and 0.94 respectively. These are within the bioequivalence acceptance range. Mebcodox 75%® and Doxycycline Kela 75%® are therefore bioequivalent and interchangeable.   


Sign in / Sign up

Export Citation Format

Share Document